Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9NPJ3
UPID:
ACO13_HUMAN
Alternative names:
Hotdog-fold thioesterase superfamily member 2; Palmitoyl-CoA hydrolase; Thioesterase superfamily member 2
Alternative UPACC:
Q9NPJ3; F5H2L4; O95549
Background:
Acyl-coenzyme A thioesterase 13, also known as Palmitoyl-CoA hydrolase, is a key enzyme that catalyzes the hydrolysis of acyl-CoAs into free fatty acids and coenzyme A, thus regulating their intracellular levels. It exhibits acyl-CoA thioesterase activity towards medium and long-chain fatty acyl-CoA substrates and can hydrolyze specific acyl-CoAs in vitro. This protein is implicated in controlling adaptive thermogenesis.
Therapeutic significance:
Understanding the role of Acyl-coenzyme A thioesterase 13 could open doors to potential therapeutic strategies.